Ohio State licenses cancer portfolio
COLUMBUS, Ohio—Ohio State University and Microlin Bio Inc. have signed an exclusive worldwide agreement licensing a sizeable portfolio of Ohio State’s cancer technology, which includes roughly 100 issued and pending microRNA patents that could lead to new ways to diagnose and treat ovarian, prostate, lung and colon cancers. Microlin Bio has also licensed a novel nucleic acid delivery technology to deliver therapies to cancer cells. As a result of this agreement, Ohio State will hold an equity position in Microlin Bio. The technologies were developed by Carlo Croce, a researcher at the Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute; Robert Lee, a researcher at the College of Pharmacy; and collaborators from the National Cancer Institute.